Cincinnati, OH, USA (FSCwire) – Callitas Health Inc. (CSE: LILY, OTCQB: MPHMD, FWB: T3F3), (the “Company” or “Callitas”) a clinical-stage company developing innovative technologies for weight management and female health and wellness, today announced that Joshua Maurice has joined the Callitas team as the Director of Sales and Marketing. Within this new role, Mr. Maurice will oversee all worldwide sales and marketing activities related to commercialization of new Callitas products.
“I am excited by the serious commitment Callitas has demonstrated to new innovative health and wellness technologies. With a pipeline of products waiting to reach the market, there could not be a more exciting time to join such a great team and company,” Mr. Maurice said. “Callitas offers a great platform for the development of new solutions that will certainly help people live healthier and more productive lives.”
Mr. Maurice brings with him over 15 years of consumer goods experience, ranging from women’s health care to dietary supplements. Mr. Maurice has overseen and coordinated multi-million dollar marketing campaigns, and has successfully integrated products into some of the largest retailers in the country. Mr. Maurice has brand and private label background expertise, as well as direct response marketing experience, which will greatly help Callitas continue to innovate within the evolving marketplace.
“As our growing portfolio of health solutions continued to expand, we quickly recognized the importance of adding an experienced sales leader to our management team,” said Gary Thompson, President and CEO of Callitas Health. “Joshua is exactly who we needed to bring onboard to concentrate on expanding our current and future distribution of unique products. I’m looking forward to seeing Joshua’s influence on Callitas as he hits the ground running,” added Mr. Thompson.
Additional Callitas News Today
The Company also announced that is has recently granted 750,000 options pursuant to its incentive stock option agreement to directors, officers and employees. These options are exercisable at $0.40 for a period of 5 years.
About Callitas Health
Formed in early 2015, Callitas Health Inc. is a clinical-stage company developing innovative technologies for obesity, weight management and female health & wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat, Extrinsa and assets from 40J’s LLC, the Company successfully launched ToConceive in North America as a clinically proven option for couples struggling with the inability to conceive. www.toconceive.com.
Callitas Health Inc. trades on the Canadian Securities Exchange (CSE) under the ticker symbol “LILY” as well as on the OTCQB as “MPHMD” and FWB (Frankfurt Stock Exchange) as “T3F3.”
For more information contact:
Callitas Investor Relations
Phone: +1 (859) 868-3131
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval and the commercialization of the rights to the Company’s biomedical & drug technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices: C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.